Editorial of special column on Drug targets and drug development for Alzheimer's disease

Editorial of special column on Drug targets and drug development for Alzheimer's disease

Bibliographic Details
Main Authors:	Wen-Xing Ding, Russell H. Swerdlow
Format:	Article
Language:	English
Published:	Elsevier 2022-04-01
Series:	Acta Pharmaceutica Sinica B
Online Access:	http://www.sciencedirect.com/science/article/pii/S221138352200106X

Similar Items

Guest Editors of Special Column on Drug Targets and Drug Development for Alzheimer’s Disease
Published: (2022-04-01)

Editorial of Special Column on Antiviral Drug Discovery and Pharmacology
by: Jun Wang, et al.
Published: (2022-04-01)

Editorial of Special Column on Drug- and Chemical-Induced Liver Injury
by: James Luyendyk, et al.
Published: (2021-12-01)

Editorial of Special Column “Novel Peptides and Peptidomimetics in Drug Discovery”
by: Jianfeng Cai, et al.
Published: (2021-09-01)

Pathogenesis of Alzheimer′s disease
by: Russell H Swerdlow
Published: (2007-10-01)

Emerging drugs and targets for Alzheimer's disease /
by: Martn̕ez, Ana, 1961-, et al.
Published: (c201)

Editorial of Special Column on RNA Therapeutics and Drug Delivery Technologies for Medical Applications
by: Wei Tao
Published: (2023-04-01)

Editorial of Special Column on A New Era of Nanobiomaterial-based Drug Delivery
by: Haijun Yu, et al.
Published: (2022-09-01)

Multi-Targets: An Unconventional Drug Development Strategy for Alzheimer’s Disease
by: Cheng-Xin Gong, et al.
Published: (2022-02-01)

Molecular drug targets and therapies for Alzheimer’s disease
by: Singh Dev, et al.
Published: (2014-09-01)

Drugs and drug delivery systems targeting amyloid-β in Alzheimer's disease
by: Morgan Robinson, et al.
Published: (2015-07-01)

The Alzheimer’s disease drug development landscape
by: Pieter van Bokhoven, et al.
Published: (2021-11-01)

The “rights” of precision drug development for Alzheimer’s disease
by: Jeffrey Cummings, et al.
Published: (2019-08-01)

Mitochondrial Dysfunction and Stress Responses in Alzheimer’s Disease
by: Ian Weidling, et al.
Published: (2019-05-01)

Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease
by: Steven N. Austad, et al.
Published: (2022-02-01)

Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer’s disease patients
by: Abdulahad Bayraktar, et al.
Published: (2023-05-01)

Approaches to rational drug development in Alzheimer's disease.
by: Iversen, L, et al.
Published: (1993)

Alzheimer's disease drug development pipeline: 2022
by: Jeffrey Cummings, et al.
Published: (2022-01-01)

Alzheimer's disease drug development pipeline: 2024
by: Jeffrey Cummings, et al.
Published: (2024-04-01)

Alzheimer's disease drug development pipeline: 2023
by: Jeffrey Cummings, et al.
Published: (2023-04-01)

Small-molecule drugs development for Alzheimer's disease
by: Weiwei Yao, et al.
Published: (2022-11-01)

Alzheimer's disease drug development pipeline: 2021
by: Jeffrey Cummings, et al.
Published: (2021-01-01)

Who funds Alzheimer's disease drug development?
by: Jeffrey Cummings, et al.
Published: (2021-01-01)

Alzheimer's disease drug development pipeline: 2020
by: Jeffrey Cummings, et al.
Published: (2020-01-01)

SHEDDING OF TREM2 AND APP AS DRUG TARGETS IN ALZHEIMER’S DISEASE
by: Stefan Lichtenthaler
Published: (2023-10-01)

Mitochondrial links between brain aging and Alzheimer’s disease
by: Heather M. Wilkins, et al.
Published: (2021-09-01)

Mitochondrial Manipulation and the Quest for Alzheimer's Treatments
by: Russell H. Swerdlow
Published: (2015-04-01)

Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase?
by: Benoit Souchet, et al.
Published: (2018-01-01)

Editorial on Special Issue “Tuberculosis Drug Discovery and Development 2019”
by: Claudia Sala, et al.
Published: (2020-09-01)

Editorial: Ethnopharmacological Studies for the Development of Drugs With Special Reference to Asteraceae
by: Sujogya Kumar Panda, et al.
Published: (2019-09-01)

A strategy to find novel candidate anti-Alzheimer’s disease drugs by constructing interaction networks between drug targets and natural compounds in medical plants
by: Bi-Wen Chen, et al.
Published: (2018-05-01)

Epigenetic drugs in Alzheimer’s disease
by: Cuadrado-Tejedor Mar, et al.
Published: (2013-10-01)

Mitochondrial Drugs for Alzheimer Disease
by: Xiongwei Zhu, et al.
Published: (2009-12-01)

Drug candidates in clinical trials for Alzheimer’s disease
by: Shih-Ya Hung, et al.
Published: (2017-07-01)

Editorial: Novel Therapeutic Target and Drug Development in Neurovascular Retinal Diseases
by: Zhuo Shao, et al.
Published: (2021-04-01)

Alzheimer's disease drug development in an evolving therapeutic landscape
by: Stacie Weninger, et al.
Published: (2024-10-01)

Drug development in Alzheimer’s disease: the contribution of PET and SPECT
by: Lieven Denis Herwig Declercq, et al.
Published: (2016-03-01)

Repurposed agents in the Alzheimer’s disease drug development pipeline
by: Justin Bauzon, et al.
Published: (2020-08-01)

APP dyshomeostasis in the pathogenesis of Alzheimer’s disease: implications for current drug targets
by: Sònia Sirisi, et al.
Published: (2024-06-01)

New Insights into Alzheimer’s Disease: Novel Pathogenesis, Drug Target and Delivery
by: Haishu Chen, et al.
Published: (2023-04-01)